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Abstract
Background: Recent reviews on placebo effects in clinical trials suggest that objective changes
following placebo treatments may not exist or, at least, have been considerably overestimated.
However, the possibility that yet unidentified subsets of parameters are responsive to placebo
treatments has not been taken into account. Therefore, the aim of the present study is to examine
the effects of placebo treatments on objectively measured outcome parameters by specifically
focusing on peripheral disease processes.
Methods:  An initial dataset was collected from a MEDLINE search for placebo-controlled,
randomized clinical trials. Trials with stable disease conditions were identified, and the effects of
placebo treatments on peripheral outcome parameters were estimated by the changes from
baseline in the placebo groups. An explorative data analysis was conducted in order to identify
parameter classes with differential responsiveness to placebo treatments. A subgroup meta-analysis
of a second dataset was performed to test whether the preliminary classification would also apply
to placebo effects derived from the comparison of placebo groups with untreated control groups.
Results: The explorative analysis of outcome parameters and strength of placebo effects yielded
a classification into responsive "physical" versus non-responsive "biochemical" parameters. In total,
50% of trials measuring physical parameters showed significant placebo effects, compared with 6%
of trials measuring biochemical parameters. A subgroup meta-analysis substantiated the differential
response (physical parameters: n = 14, Hedges' pooled effect size g = 0.34, 95% CI 0.22 to 0.46;
biochemical parameters: n = 15, g = 0.03, 95% CI -0.04 to 0.10). The subanalysis of the second
dataset supported the classification and revealed a significant improvement for physical parameters
(n = 20, g = 0.22, 95% CI 0.07 to 0.36) and a deterioration for biochemical parameters (n = 6, g =
-0.17, 95% CI -0.31 to -0.02).
Conclusion:  The results suggest that placebo interventions can improve physical disease
processes of peripheral organs more easily and effectively than biochemical processes. This
differential response offers a good starting point for theoretical considerations on possible
mediating mechanisms, and for future investigations in this field.
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Background
Since the introduction of double-blind randomized con-
trolled trials, which have become the gold standard for
assessing the efficacy of pharmacological treatments,
reports on marked therapeutic changes in the placebo
arms of the trials have led to the widespread belief that
placebos have powerful effects [1]. However, in 1997,
Kienle and Kiene [2] critically reviewed the placebo litera-
ture and concluded that the existing reports on powerful
placebo effects do not withstand strong scientific criteria.
Instead, most of the reported placebo effects could be
explained by factors unrelated to the placebos, such as
spontaneous improvement, additional treatment, or sta-
tistical regression to the mean. In accordance with other
authors, they concluded that the "true" placebo effect [3]
could best be identified by comparing the effects in the
placebo arm of a study with those in an untreated control
arm.
This approach was consequently followed by Hróbjarts-
son and Gøtzsche in their meta-analysis on clinical pla-
cebo effects. They analyzed 114 trials [4], and later an
additional 44 trials [5,6], which contained both a placebo
arm and a no-treatment control arm. Their analyses con-
firmed that the overall effect of placebo interventions,
when compared with no intervention, is smaller than pre-
viously believed. They found a significant placebo effect
only for subjective, patient-reported symptoms, most
importantly pain. For observer-reported parameters, they
did not find statistical evidence for a placebo effect.
Slightly different predefinitions, however, do yield a small
but significant placebo effect for observer-reported out-
comes [7].
One plausible reason for the small or even absent placebo
effect in these meta-analyses could be that placebo inter-
ventions do not affect all observer-reported outcomes
equally. Instead, it might be that only a subset of outcome
parameters is responsive to placebo treatment.
The aim of the present study was to examine whether pla-
cebo treatment can objectively improve peripheral disease
processes. We focused on peripheral disease processes
because evidence for placebo effects in this field is rather
scarce. Therefore, we analyzed placebo effects on objec-
tively measured outcome parameters from peripheral
organs, tissues, and body fluids that were collected from
two independent datasets of clinical trials.
The first dataset was derived from a MEDLINE search for
placebo-controlled, clinical trials. Because the selected tri-
als did not include untreated control groups, we restricted
the dataset to trials on stable disease conditions, from
which the effects of placebo treatments could be esti-
mated by baseline changes within the placebo groups. We
examined whether placebo treatments had differential
effects on parameter subtypes and tried to establish an
appropriate parameter classification. To test whether this
preliminary classification would also apply to placebo
effects derived from the comparison of placebo groups
with untreated control groups, we added a subgroup
meta-analysis of the trials collected by Hróbjartsson and
Gøtzsche [6], using those with peripheral parameters as
outcomes.
Methods
Definition of peripheral outcome parameters
Peripheral outcome parameters were defined as parame-
ters measuring disease processes in peripheral organs, tis-
sues, and body fluids.
Analysis of placebo effects in clinical trials derived from a 
MEDLINE search
Trial identification and selection
The first dataset was derived from a literature search for
placebo-controlled clinical trials published in five leading
medical journals (Annals of Internal Medicine, British Med-
ical Journal, Journal of the American Medical Association, The
Lancet and New England Journal of Medicine) during the
decade from 1991 to 2000. For this, a MEDLINE search
was conducted by using the search-terms "placebo", "pla-
cebo(-)controlled" and "double(-)blind". This resulted in
1723 hits, among them 1689 double-blind, randomized
trials using placebo controls. From these, all trials on non-
clinical populations were excluded, as well as trials inves-
tigating a psychological, neurological or psychiatric disor-
der, or reporting exclusively on subjective symptoms.
Trials lacking a classic placebo control group were also
excluded. Furthermore, in order to select only trials with
stable disease conditions, trials were excluded when the
disease was expected to either improve or deteriorate dur-
ing the study period, irrespective of experimental treat-
ment, e.g., due to the natural course of the disease, or to
co-interventions. For example, mild-to-moderate hyper-
tension would be considered rather stable over a 4-week
period in otherwise healthy patients but unstable in
women developing hypertension during pregnancy. Sim-
ilarly, hypercholesterolaemia would be considered rather
stable over a 12-week period in patients maintaining their
usual diet, but unstable when patients received dietary
advice in addition to double-blind treatment. Thus, we
searched for trials in which the baseline data provided an
appropriate reference to interpret the changes observed
within the placebo groups as the effect of the placebo
intervention itself and not of other, placebo-unrelated fac-
tors. Finally, from the remaining trials, we excluded all tri-
als lacking relevant details to determine the significance of
baseline changes within the placebo groups. In total, 34
trials [8-41] investigating chronic stable clinical condi-
tions and reporting on at least one peripheral outcomeBMC Medicine 2007, 5:3 http://www.biomedcentral.com/1741-7015/5/3
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parameter fulfilled all criteria and were included in the
analysis (Table 1).
Data extraction
From the 34 studies meeting the selection criteria, we
extracted the baseline changes of peripheral outcome
parameters within the placebo groups. When several
parameters or time points had been measured, we ana-
lyzed the parameter or measurement with the largest
effect size during the treatment period because we aimed
at identifying outcome parameters most strongly affected
by placebo treatment. From studies using a crossover
design, we analyzed only the data of the group receiving
placebo treatment first to avoid possible unblinding
effects and drug carry-over effects.
Data analysis
For estimating the overall placebo effect on peripheral
outcome parameters, we combined the effects of single tri-
als by performing a meta-analysis based on 29 of the 34
trials. In five trials [10,21,31,36,37], data were not suffi-
cient for the meta-analysis as only significance values of
the effects of placebo treatment had been reported.
To start our explorative analysis, we determined the signif-
icance of the baseline changes within the placebo group of
each trial. For this, we used the reported results of statisti-
cal testing or, when necessary, the means and measures of
variability for performing two-tailed t-tests to estimate sig-
nificance. We then identified possible common character-
istics of parameters with significant or non-significant
changes during placebo treatments. To substantiate the
resulting dichotomous classification, we performed sub-
group meta-analyses of the n-weighted standardized
mean differences for each parameter subgroup.
In addition, to compare the efficacy of placebo relative to
active treatment, we extracted the baseline changes of the
analyzed parameters for the active treatment groups as
well, and computed their n-weighted standardized mean
differences. In cases with more than one active treatment
arm, we selected the data of the most effective active treat-
ment, according to study results. Placebo efficacy relative
to active treatment was then estimated by dividing the
standardized mean difference of the effect of placebo
treatment by that of the active treatment.
Analysis of placebo effects in clinical trials that included a 
no-treatment control group
Trial selection and data extraction
The second dataset for analyzing placebo effects on
peripheral outcome parameters was collected from the
updated review on placebo effects by Hróbjartsson and
Gøtzsche [5,6]. First, we selected all 56 trials with
observer-reported continuous outcomes. These included
13 trials with corresponding patient-reported and
observer-reported continuous outcomes, from which only
the patient-reported outcomes had been included in the
Table 1: Reasons for exclusion and number of excluded trials during the selection process of the first dataset
Reasons for exclusion n
Lack of placebo-controlled, double-blind, randomized trial
Review, article, or comment 272
No placebo used 186
Lack of double-blinding or randomization 96
Kind of investigated symptom or condition
No clinical condition 44
Psychological, neurological or psychiatric condition 106
Subjective symptom 67
No classic placebo control group
Placebo as a dummy to maintain blinding of experimental treatments 147
Placebo as a control of an add-on treatment 74
Lack of stable disease condition
Medical intervention preceding experimental treatment 120
Co-medication changed during study 33
Acute condition 79
Developmental disorder 20
Trial focus on relapse or prevention 131
Trial focus on death or other serious events 113
Trial focus on long-term development of disease 121
Miscellaneous
Crossover design and results not separated by sequence 23
Native physiological parameter not reported 17
Insufficient detail to estimate placebo effect 40
Total 1689BMC Medicine 2007, 5:3 http://www.biomedcentral.com/1741-7015/5/3
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main analysis by Hróbjartsson and Gøtzsche [6]. We
excluded all trials on psychological, psychiatric or neuro-
logical conditions and those reporting exclusively on sub-
jective symptoms, thereby selecting 26 trials that used
peripherally measured parameters as outcomes [42-67].
Because the no-treatment groups controlled for unstable
disease conditions due to natural or iatrogenic factors as
well as for regression to the mean, this selection, in con-
trast to the first dataset, also included trials investigating
acute or post-surgical conditions [46,47,59-62,67], as well
as one trial in which subjects had not had a fully devel-
oped disease condition but were selected because of high
normal blood pressure values [57], a procedure highly
sensitive to the phenomenon of regression to the mean
[68].
Data analysis
The results of the 26 trials were combined by calculating a
meta-analysis of the n-weighted standardized mean differ-
ences for the post-intervention effects in the placebo and
no-treatment groups. Subanalyses of parameter sub-
groups according to our classification were performed
identically.
Statistical analysis
For all meta-analyses, n-weighted standardized mean dif-
ferences and 95% confidence intervals for the respective
placebo effects were calculated using Hedges' adjusted
effect size estimation and random effect models. To test
for heterogeneity, χ2 and I2 statistics were performed. The
computer program RevMan (version 4.2 for Windows)
was used to calculate the meta-analysis measures. We allo-
cated positive signs to effects favoring placebo treatment.
For all statistical tests, P < 0.05 (two-tailed) was consid-
ered significant.
Results
Analysis of placebo effects in clinical trials derived from a 
MEDLINE search
All 34 placebo-controlled trials [8-41] meeting our inclu-
sion criteria investigated pharmacological treatment,
which was administered in 17 different clinical conditions
(Additional file 1; Table 2, summarizing the data of the
first dataset).
The meta-analysis of the baseline changes within the pla-
cebo groups of the 29 trials providing sufficient data
showed a significant overall improvement of parameters
during placebo treatment (Hedges' pooled effect size g =
0.21, 95% CI 0.12 to 0.31, P < 0.0001) with a high level
of heterogeneity between studies (χ2 = 63.37, P = 0.0001,
I2 = 55.8%).
The explorative analysis revealed that significant placebo
effects were predominantly found for parameters measur-
ing physical processes, e.g., blood pressure, or forced
expiratory volume in 1 second (FEV1). Therefore, all types
of physical outcome parameters were collected in one
class, which was named "physical parameters". The
remaining parameters, less frequently responding to pla-
cebo treatments, appeared to represent biochemical proc-
esses measured in peripheral body fluids and tissues, e.g.,
cholesterol and cortisol. Therefore, they were all taken
together in one alternative class, which was named "bio-
chemical parameters". To be more precise, 8 of 16 trials
(50%) using physical parameters as outcomes reported
significant placebo effects compared with only 1 of 18 tri-
als (6%) using biochemical parameters. This difference
was statistically significant (Fisher's exact probability test,
P < 0.01).
To further substantiate this classification, we performed
subanalyses for both groups of parameters. This revealed
a significant placebo effect for physical parameters with a
pooled effect size of g = 0.34 (95% CI 0.22 to 0.46, P <
0.0001), but an effect size close to zero for biochemical
parameters (g = 0.03, 95% CI -0.04 to 0.10, P = 0.41) (see
Figure 1). The differentiation between physical and bio-
chemical parameters reduced heterogeneity (χ2 = 24.63, P
= 0.03, I2 = 47.2%; and χ2 = 6.39, P = 0.96, I2 = 0%, respec-
tively). Sensitivity analyses revealed that heterogeneity
within the group of physical parameters was due to one
outlier [20], and the exclusion of this study substantially
reduced heterogeneity (I2 = 0%).
All trials of the first dataset provided an active treatment
arm. The median placebo efficacy ratio relative to active
treatment in the total dataset was 0.26 (interquartile range
(IQR) 0.05 to 0.37). For the subgroup of physical param-
eters it was 0.35 (IQR 0.27 to 0.42), or about one third of
the active treatment effect, whereas for the subgroup of
biochemical parameters, the ratio was close to zero (0.05;
IQR -0.10 to 0.13). The difference between placebo effi-
cacy ratios for physical and biochemical parameters was
significant (Mann-Whitney U test, P < 0.001).
Analysis of placebo effects in clinical trials that included a 
no-treatment control group
The dataset of Hróbjartsson and Gøtzsche [6] provided 26
trials with peripheral parameters as outcomes [42-67]
(Additional file 2: Table 3, summarizing the data of the
second dataset). In total, pharmacological treatment was
investigated in 13 trials, physical treatment in 5, psycho-
logical treatment in 5, and placebo treatment in 3. These
treatments were administered in 12 different disease con-
ditions. The no-treatment control group was provided by
a waiting-list control in one trial, and by all patients in
seven trials using a crossover design.BMC Medicine 2007, 5:3 http://www.biomedcentral.com/1741-7015/5/3
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Meta-analysis of the first dataset Figure 1
Meta-analysis of the first dataset. Standardized mean differences (placebo versus baseline) for physical and biochemical 
parameters in the 29 trials of the first dataset, retrieved from a MEDLINE search. Black squares indicate single effect sizes, 
white squares are the subgroups' mean effect sizes, and whiskers the 95% CI. Reference numbers are given in square brackets. 
Positive values favor placebo treatment.
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The meta-analysis of all 26 trials failed to show a signifi-
cant overall improvement due to placebo treatment (g =
0.11, 95% CI -0.01 to 0.24, P = 0.08), and heterogeneity
between studies was high (χ2 = 47.24, P  = 0.005, I2 =
47.1%). The application of our classification showed a
significant improvement during placebo treatment for
physical parameters (n = 20, g = 0.22, 95% CI 0.07 to
0.36, P = 0.003), whereas for biochemical parameters it
showed the opposite (n = 6, g = -0.17, 95% CI -0.31 to -
0.02, P = 0.02) (see Figure 2). There was slight heteroge-
neity within the group of physical parameters (χ2 = 30.64,
P = 0.04, I2 = 38.0%), but not within the group of bio-
chemical parameters (χ2 = 1.36, P = 0.93, I2 = 0%).
To confirm that the inclusion of acute and post-surgical
conditions in our second dataset did not significantly
influence the results, a reanalysis with these trials
excluded was performed, thereby focusing on stable dis-
ease conditions. The effect sizes within the physical and
biochemical parameter subgroups remained comparable
with that of our main analysis (physical parameters: n =
15, g = 0.21, 95% CI 0.01 to 0.41, P = 0.04; biochemical
parameters: n = 4, g = -0.17, 95% CI -0.32 to -0.01, P =
0.03).
Discussion
Our results indicate that placebo interventions can
improve objective measures of peripheral disease proc-
esses. They furthermore suggest that placebo interventions
do not improve all kinds of peripheral outcome parame-
ters equally, but primarily those reflecting physical disease
processes.
The meta-analysis of placebo effects in the first dataset
(collected from a MEDLINE search for placebo-controlled
clinical trials) revealed a significant overall improvement
of peripheral outcome parameters by placebo treatments.
The explorative analysis indicated that significant effects
occurred more frequently on physical than on biochemi-
cal parameters. Accordingly, an overall placebo effect
across trials was only found within the subgroup of phys-
ical parameters. In comparison to the pharmacological
medication, the administration of placebos improved
physical parameters on average by one-third – a remarka-
ble efficacy, not found for biochemical parameters. These
results already suggest that placebo interventions affect
physical parameters more frequently and strongly than
biochemical parameters.
However, our classification was derived from clinical pla-
cebo-controlled trials without a no-treatment arm. These
trials had not been designed to analyze placebo effects but
to estimate the effect of the active medication against pla-
cebo control groups. Therefore, factors not due to placebo
treatment may have contributed to the changes in the pla-
cebo groups in such trials, e.g., the natural course of the
disease, and regression to the mean. We attempted to con-
trol for these factors by focusing on trials with otherwise
stable disease conditions and tried to minimize the risk of
regression to the mean by excluding trials on non-random
samples selected by screening from a healthy population
[68]. However, even in stable chronic conditions, symp-
toms may vary over time, and the possibility that some of
the improvement on physical parameters may be due to
regression cannot be fully excluded by the present data.
Therefore, to further substantiate our classification, we
made use of the database of Hróbjartsson and Gøtzsche,
which contains a complete collection of trials including
both a placebo and a no-treatment control group [5,6].
Again, the subanalysis of trials with peripheral outcome
parameters revealed a significant improvement from pla-
cebos compared with no treatment for the subgroup of
physical parameters only. In fact, the analysis even
showed a significant negative effect of placebos on bio-
chemical parameters. However, as the number of trials
reporting on biochemical parameters was small, this find-
ing should be treated with caution.
A possible limitation in the present study is that physical
and biochemical parameters were measured in different
trials. Therefore, confounding variables, such as differ-
ences in study design or patient characteristics, may have
biased the results. However, to use trials in which both
parameters are measured in the same condition appears to
be problematic, as the outcomes most probably would be
coupled, i.e., any physical improvement would be
expected to entail changes in biochemical parameters.
Hence, our approach to compare trials with either type of
parameter may provide the best available evidence to test
the appropriateness of our classification. Furthermore, the
fact that a remarkable difference in placebo effectiveness
between physical and biochemical parameters was found
in two different datasets renders the possibility of such a
bias quite unlikely.
The responsiveness of physical parameters to placebo
treatments becomes plausible when possible mechanisms
mediating the effect are considered. Presumably, patients
are able to monitor the state of their inner organs by sen-
sory feedback – that is, by visceral perception [69] or by
somatic perception (e.g. when experiencing respiratory
effort in asthma [70] or ballistic movements in hyperten-
sion [71]). They may thus be able to monitor fluctuations
in organ states rather quickly. During placebo treatment,
the belief of the patient in being treated may result in
selective attention to symptom improvement [72]. The
momentary experience of symptom improvement may
then act as a reward and positively reinforce preceding
changes of autonomic function. Thus, visceral learningBMC Medicine 2007, 5:3 http://www.biomedcentral.com/1741-7015/5/3
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Meta-analysis of the second dataset Figure 2
Meta-analysis of the second dataset. Standardized mean differences (placebo versus no treatment) for physical and bio-
chemical parameters in the 26 trials of the second dataset, selected from a published review on placebo effects [6]. For details, 
see Figure 1.
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due to a mechanism similar to operant conditioning [73]
may occur, in which the reward is internally provided
[74]. The fast neural feedback from inner organs to corti-
cal brain centers, which are involved in autonomic con-
trol [75,76], renders physical disease processes ideally
suited for this kind of central modification.
Although many of the biochemical parameters are also
modulated by the autonomic nervous system, there are
several reasons for these being less placebo-sensitive. First,
patients may have little or no visceral or somatic sensory
feedback to monitor parameter changes, e.g., of insulin-
like growth factor-1 or cholesterol, whether spontane-
ously occurring or induced by treatment. Second, even in
cases when the actual concentration of a biochemical
parameter can be estimated by the patient (e.g., blood glu-
cose levels [77]) the nonspecific character of the symp-
toms on which these estimations may be based, and
hence the difficulty in identifying spontaneous improve-
ment, may prevent conditioning occurring. For example,
varying blood glucose levels may affect thirst, hunger, and
mouth dryness [77], symptoms that are also influenced by
other factors, most importantly, food and water ingestion.
Third, the latency between spontaneous parameter
changes and the perception of improvement may be too
long to provide contingent feedback [78], e.g., fibrinolytic
activity in the healing of venous leg ulcers. Thus, most of
the biochemical parameters may lack an essential element
for placebo effects to be established, namely, the experi-
ence of momentary improvements due to autonomic
changes.
A plausible explanation for the deterioration of biochem-
ical parameters in the second dataset might be related to
the diet-sensitivity of some of the parameters [63-66]:
Patients in placebo groups, believing they are being
treated, may become less cautious in following their diet,
while untreated patients, necessarily knowing about the
lack of treatment, may pay more attention to their diet.
Alternatively, an unblinding of placebo recipients during
the trial may lead to frustration and therefore to less com-
pliance with the dietary regimen.
One frequently discussed mediating mechanism of pla-
cebo effects is the patient's expectation of clinical
improvement, which can be raised, for example, by verbal
suggestions accompanying placebo treatment [79,80].
Expectation and operant conditioning may complement
each other. Learning theory emphasizes the importance of
response-specific expectations for the performance of
operant conditioning tasks [81]. Thus, the patient may
direct his/her attention to symptom improvement
because he/she is expecting a clinical benefit. In this sense,
expectation may be necessary to both initiate and main-
tain the process of operant conditioning. It has recently
been demonstrated that in patients with parkinsonian dis-
ease, both the expectation and the actual experience of a
clinical benefit during placebo treatment activates the
inner-brain reward circuitry [74,82]. This experimental
result fits well with the hypothesis that both mechanisms
(expectation and operant conditioning) are involved in
the mediation of placebo effects.
Classical drug conditioning is also considered one of the
mechanisms mediating placebo effects [79,80]. Classi-
cally-conditioned drug effects are, however, expected to
extinguish after repeated administration of an inactive
agent, and therefore should diminish over the course of
clinical trials, in which treatment usually is administered
repeatedly [83]. Positive outcomes in the placebo groups
of clinical trials are therefore more likely to be induced
and maintained by expectation rather than by classical
conditioning.
Notably, there is evidence from experimental studies that
expectations raised by placebo suggestions can affect
physical parameters of peripheral organs, e.g., gastric and
pulmonary function [84-86], but not biochemical param-
eters, i.e., growth hormone and cortisol [87]. These exper-
imental results lend support to the present result that
physical and biochemical parameters respond differen-
tially to placebo treatments, with only physical parame-
ters being affected by expectation, and thus displaying
placebo effects in clinical trials.
In this study, we were able to identify different kinds of
peripheral outcome parameters as one reason for the het-
erogeneity of placebo effects on observer-reported out-
comes. The differential placebo responsiveness of physical
versus biochemical parameters should be taken into
account when designing future pharmacological studies.
A question that ties in with the present results concerns
the putative specificity of placebo effects. Depending on
the type of disease (e.g., psychiatric, neurological, inter-
nal), on the information delivered to the patient, and on
the patient's former experiences with treatments, the
effects of placebo interventions may differ, and different
mechanisms may be involved. To disentangle the specific
components of placebo treatments under different cir-
cumstances and to work out their effects represents a
major challenge for future placebo research.
Conclusion
Our results indicate that placebo treatments of peripheral
disease processes can affect physical parameters more eas-
ily and strongly than biochemical parameters. This differ-
entiation holds true for both datasets we tested, i.e.,
conventional placebo-controlled clinical trials, and clini-
cal trials that included a no-treatment arm. As a corollary,
it follows that placebo-responsive subgroups may also beBMC Medicine 2007, 5:3 http://www.biomedcentral.com/1741-7015/5/3
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identified in datasets in which global averages conceal
such specific responses.
Although much progress has been made in the past dec-
ade in understanding the biological basis of placebo
effects in neurological conditions, e.g., pain and parkinso-
nian disease, the mechanisms that mediate placebo effects
on peripheral organ systems still await to be further eluci-
dated. The differential placebo responsiveness of physical
versus biochemical parameters, as disclosed in the present
study, offers a good starting point for theoretical consider-
ations on possible mediating mechanisms, as well as for
future investigations in this field.
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